Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988161 | 0.85 | HTT (0.71) | MAPTKMT2ANOTUMPYGLCA1 | |
| SCHEMBL28094523 | 0.85 | CYP1A2 (0.68) | KMT2ACA1CA2CA12CA7 | |
| SCHEMBL156299 | 0.83 | HTT (0.73) | PYGLCA1CA2CA12CA7 | |
| SCHEMBL30307554 | 0.83 | HTT (0.73) | PYGLCA1CA2CA12CA7 | |
| SCHEMBL29599043 | 0.83 | LMNA (0.55) | KMT2ACA1CA2CA12CA7 | |
| SCHEMBL660929 | 0.83 | LMNA (0.55) | KMT2ACA1CA2CA12CA7 | |
| SCHEMBL22980803 | 0.83 | NOTUM (0.48) | MAPTKMT2ANOTUMPYGLCA1 | |
| SCHEMBL1110800 | 0.83 | NOTUM (0.58) | MAPTKMT2ANOTUMCA1CA2 | |
| SCHEMBL28230672 | 0.83 | NOTUM (0.48) | MAPTKMT2ANOTUMPYGLCA1 | |
| SCHEMBL27342407 | 0.83 | RAB9A (0.46) | MAPTKMT2ANOTUMCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4446312-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118488944-A | Nitrogen-containing heterocyclic compound having Nrf2 activation | 中外制药株式会社 | 2024-08-13 | — | — | CN | disclosed |
| CN-114728910-B | Pyrazole derivative for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023132369-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | 中外製薬株式会社 | 2023-07-13 | — | — | WO | disclosed |
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-114728910-A | Pyrazole derivatives for FGFR inhibitor and preparation method thereof | 上海奕拓医药科技有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| US-6420558-B1 | COMPOUNDS WITH AMIDINE GROUPS ANTAGONISTIC ACTIVITY, CELL ADHESION INHIBITORY ACTIVITY, HUMAN PLATELET AGGREGATION INHIBITORY ACTIVITY, AND THERAPEUTIC AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-0635498-B1 | Quinazoline derivatives and their use as anti-cancer agents | SYNGENTA LTD (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | disclosed |
| US-5580870-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0602851-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1996-10-09 | — | — | EP | disclosed |
| US-5475001-A | Quinazoline derivatives | ZENECA LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| WO-1995003283-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | ZENECA LIMITED (GB) | 1995-02-02 | — | — | WO | disclosed |
| EP-0635498-A1 | Quinazoline derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
| CN-1094043-A | Quinazoline derivant | ZENECA LTD (GB) | 1994-10-26 | — | — | CN | disclosed |
| EP-0602851-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1994-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | KEAP1, NFE2L2, BACH1 | MAPT 4531/4885KMT2A 3035/4885NOTUM 4321/4885 |
| US-20250171457-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | MAPT 4531/4885KMT2A 3035/4885NOTUM 4321/4885 |
| US-20220298143-A1 | Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof | FGFR1, FGFR2, FGFR3 | MAPT 3854/4885KMT2A 2107/4885NOTUM 141/4885 |
| US-20250084093-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | KEAP1, NFE2L2, BACH1 | MAPT 4579/4885KMT2A 3087/4885NOTUM 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.